Ivermectin, an FDA-approved antiparasitic drug derived from avermectin, has gained significant attention in oncology due to its potential antitumor effects observed in preclinical studies. Originally developed to treat parasitic infections such as river blindness and strongyloidiasis, it is now being explored for drug repositioning in cancer treatment. The interest stems from its ability to target multiple cancer pathways at doses that appear nontoxic to healthy cells, offering a potentially cost-effective adjunct to existing therapies. However, clinical evidence in humans remains limited, and experts strongly caution against self-medication, emphasizing the need for rigorous clinical trials.
